WO2011041376A1 - Facteur modifié de stimulation des colonies de granulocytes (g-csf) - Google Patents

Facteur modifié de stimulation des colonies de granulocytes (g-csf) Download PDF

Info

Publication number
WO2011041376A1
WO2011041376A1 PCT/US2010/050671 US2010050671W WO2011041376A1 WO 2011041376 A1 WO2011041376 A1 WO 2011041376A1 US 2010050671 W US2010050671 W US 2010050671W WO 2011041376 A1 WO2011041376 A1 WO 2011041376A1
Authority
WO
WIPO (PCT)
Prior art keywords
csf
peg
protein
pegylated
terminus
Prior art date
Application number
PCT/US2010/050671
Other languages
English (en)
Inventor
Lihsyng S. Lee
Abraham Abuchowski
Gerry Gitlin
Original Assignee
Prolong Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43826620&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011041376(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prolong Pharmaceuticals filed Critical Prolong Pharmaceuticals
Publication of WO2011041376A1 publication Critical patent/WO2011041376A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • This invention relates to novel protein conjugates, particularly pegylated proteins, and their methods of making and use.
  • One aspect of the present invention relates to pegylated-G-CSF having unexpected efficacy and stability.
  • Neutropenia can put some patients at risk for severe infections and may interrupt chemotherapy treatment.
  • complications associated with a low white blood cell count are the most common causes of dose reductions or delays in chemotherapy (see Link, et al. (2001) Cancer.;92: 1354-1367; Lyman, et al. (2003) J Clin Oncol. 21 :4524-4531; and Lyman, et al. (2002) Am J Med. 112:406-411).
  • G-CSF Granulocyte colony stimulating factor
  • the mouse version of G-CSF was purified from explanted tissues in 1983 and the human equivalent purified from a cancer cell line grown in culture inadveretently expressing G-CSF in high concentration sin 1985 (see e.g. Welte, et al. (1985) PNAS USA 82:1526-30).
  • the human G- CSF was found to be a glycoprotein around 19kD which was variably acidic depending on the carbohydrate component. It was later found that the carbohydrate component was optional for biologic activity.
  • PEG polyethylene glycol
  • biopharmaceutical carriers given their high degree of biocompatibility. PEGylation can modify certain characteristics of biopharmaceuticals without altering their function, thereby enhancing the therapeutic effect.
  • polyethylene glycol molecules are connected to the protein via a reactive group found on the protein.
  • Amino groups such as those on lysine residues or at the N-terminus, are convenient for such attachment.
  • PEG molecules have been attached through amino groups on polypeptides using methoxylated PEG ("mPEG") having different reactive moieties.
  • mPEG methoxylated PEG
  • Such polymers include mPEG-succinimidyl succinate, mPEG-succinimidyl carbonate, mPEGimidate, and mPEG-cyanuric chloride.
  • PEG can be coupled to active biopharmaceuticals through the hydroxyl groups at the ends of the polymer chain using a variety of chemical methods.
  • therapeutic polypeptides such as interleukins (Knauf, M. J. et al., J. Biol. Chem. 1988, 263, 15,064; Tsutsumi, Y. et al, J. Controlled Release 1995, 33, 447), interferons (Kita, Y. et al, Drug Des. Delivery 1990, 6, 157), catalase (Abuchowski, A. et al, J. Biol. Chem. 1977, 252, 3, 582), superoxide dismutase (Beauchamp, C. O.
  • site specific rather than random pegylation is desirable.
  • Site-specific pegylation at the N- terminus, side chain and C-terminus of a potent analog of growth hormone-releasing factor has been performed through solid-phase synthesis (Felix, A. M. et al., Int. J. Peptide Protein Res. 1995, 46, 253).
  • PCT WO 2006/094530 to Siegried, Ltd. describes certain di-pegylated protein conjugates and processes for their preparation.
  • Examples of dipegylated G-CSF are provided, in which the products are dipegylated at both the N-terminus and Lysl7 or at the N-terminus and Lys35.
  • Site-specific mutagenesis is a further approach which has been used to prepare polypeptides for site-specific polymer attachment.
  • U.S. Patent No. 6,646,110 describes polypeptide conjugates that exhibit G-CSF activity and have an amino acid residue that comprise and attachment group for a PEG or oligosaccharide moiety inserted. These can include lysine, glutamic acid, cysteine or aspartic acid.
  • the present invention is based on the production of novel forms of monopegylated proteins, e.g., granulocyte colony stimulating factor ("G-CSF”) that are G-CSF.
  • G-CSF granulocyte colony stimulating factor
  • DMSO dimethyl sulfoxide
  • the use of dimethyl sulfoxide (“DMSO”) in the methods of producing PEG-linked proteins by reductive alkylation drives the PEG conjugation only to sites at or near the N-terminus.
  • the process generally can drive the PEG to the lysine residue that is closest to the N-terminus.
  • the invention provides a G-CSF molecule that includes a PEG-molecule linked to Lysl6 (Lys 17 if a terminal methionine is included).
  • the invention also provides a method of linking an aldehyde-reactive PEG to a protein in the presence of DMSO.
  • the invention relates to a composition
  • a composition comprising at least one population of G-CSF proteins wherein each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule and at least a 30% of the composition is not N- terminal pegylated.
  • each G-CSF molecule is covalently linked to a single polyethylene glycol molecule ("monopegylated G-CSF") and at least 30%> of the composition is not N-terminally pegylated.
  • the composition comprises at least 80%> monopegylated G-CSF wherein at least 30%> of the composition is not N-terminally pegylated.
  • the composition comprises at least 85%, at least 90%) or at least 95% monopegylated G-CSF molecules wherein at least 30%> of the composition is not N-terminally pegylated.
  • each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule through a particular lysine residue.
  • the invention comprises a composition having at least one G- CSF molecule covalently linked to at least one polyethylene glycol molecule via the amino terminus of the GCSF protein through an amine linkage.
  • the invention comprises a composition having at least one G-CSF molecule covalently linked to at least one polyethylene glycol molecule through Lysl6 (Lysl7 if an N-terminal methionine residue is counted).
  • the ratio of the N-terminally pegylated molecules to a second population, especially a second population at Lysl6 can range from less than about 1 to about 100, about 10 to about 90, about 20 to about 80, about 30 to about 70, about 40 to about 60, about 50 to about 50, about 60 to about 40, about 70 to about 30, wherein less than about 1 includes an amount undetectable using standard methods known in the art.
  • a substantially homogeneous composition comprising a monopegylated protein wherein at least 30% of the protein molecules are not pegylated at the N-terminal.
  • the composition comprises at least 30% monopegylated proteins which are pegylated at a lysine residue within 100 amino acids of the N-terminal.
  • the lysine is within 80, within 70, within 60, within 50, within 40, within 30, within 20, within 19, within 18, within 17, within 16, within 15, within 14, within 13, within 12, within 11 , within 10, within 9, within 8, within 7, within 6, within 5, within 4, within 3 or within 2 amino acid residues from the N-terminal.
  • the invention relates to a pharmaceutical formulation comprising at least one population of G-CSF proteins wherein each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule, optionally in a
  • the carrier is substantially protein free.
  • the pharmaceutical formulation comprises at least one population of G-CSF proteins wherein each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule and at least a 30% of the composition is not N-terminal pegylated.
  • each G-CSF molecule is covalently linked to a single polyethylene glycol molecule ("monopegylated G-CSF") and at least 30%> of the composition is not N-terminally pegylated.
  • the formulation comprises at least 80% monopegylated G-CSF wherein at least 30% of the composition is not N-terminally pegylated.
  • the formulation comprises at least 85%, at least 90% or at least 95% monopegylated G-CSF molecules wherein at least 30%> of the composition is not N-terminally pegylated.
  • each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule through a particular lysine residue.
  • the formulation includes at least one G- CSF molecule covalently linked to at least one polyethylene glycol molecule via the amino terminus of the GCSF protein through an amine linkage.
  • the formulation comprises at least one G-CSF molecule covalently linked to at least one polyethylene glycol molecule through Lysl6 (Lysl7 if an N-terminal methionine residue is counted).
  • the ratio of the N-terminally pegylated molecules to a second population, especially a second population at Lysl6 can range from less than about 1 to about 100, about 10 to about 90, about 20 to about 80, about 30 to about 70, about 40 to about 60, about 50 to about 50, about 60 to about 40, about 70 to about 30, wherein less than about 1 includes an amount undetectable using standard methods known in the art.
  • the G-CSF molecules and compositions of the invention are expected to exhibit prolonged stability under standard storage conditions, i.e., storage at standard temperature, e.g., about 25°C for at least three months.
  • the protein- free carrier is serum-free, albumin-free or human serum albumin-free ("hsa-free")).
  • the pharmaceutical formulations may be stored for extended period of time without substantial and/or detectable degradation of G-CSF as determined by methods described herein and/or known in the art.
  • the pharmaceutical formulations of the invention are stable (i.e., do not exhibit detectable and/or do not exhibit substantial degradation) as determined at least 15 months after storage at about -20°C or 4°C.
  • the pharmaceutical formulations of the invention are stable (i.e., do not exhibit detectable and/or do not exhibit substantial degradation) as determined at least 10 months after storage at about 25°C or about 37°C.
  • formulations of the invention may be assessed by any method known in the art.
  • the stability of the pharmaceutical formulations of the invention is assessed by monitoring alteration in the protein concentration over time as determined by a bicinchoninic acid ("BCA") protein assay.
  • BCA bicinchoninic acid
  • the stability of the pharmaceutical formulations of the invention is assessed by indication of protein degradation (i.e., G-CSF conjugate degradation) over time as determined by SDS PAGE analysis.
  • the stability can be measured by analyzing breakdown of the product by an HPLC.
  • the stability of the pharmaceutical formulations of the invention is assessed by monitoring the activity of said formulation over time, wherein said activity is determined by any in vitro or in vivo method known in the art for determination of activity of said formulation ⁇ e.g., G-CSF activity).
  • the activity of a pharmaceutical formulation of the invention comprising a plurality of G-CSF conjugates is evaluated by the ability of said pharmaceutical formulation in an invitro bioassay utilizing a G-CSF dependent clone of murine 32D cells.
  • the acitivyt of the formulation is measured in vivo in its capacity to alter white blood cell count in experimental animals, such as hamsters.
  • a pharmaceutical formulation comprising a monopegylated protein wherein at least 30% of the protein molecules are not pegylated at the N-terminal.
  • the formulation comprises at least 30% monopegylated proteins which are pegylated at a lysine residue within 100 amino acids of the N-terminal.
  • the lysine is within 80, within 70, within 60, within 50, within 40, within 30, within 20, within 19, within 18, within 17, within 16, within 15, within 14, within 13, within 12, within 11, within 10, within 9, within 8, within 7, within 6, within 5, within 4, within 3 or within 2 amino acid residues from the N-terminal.
  • a method of increasing white cell count in a host comprising administering a pharmaceutical formulation of the invention to a host in need thereof.
  • the host is human.
  • the hosts are at risk of or suffering from neutropenia.
  • the hosts are being treated with an agent that decreases their white blood cell count.
  • the hosts have decreased endogenous levels of G-CSF.
  • the hosts are undergoing radiation treatment.
  • the hosts can be suffering from lung cancer, lymphoma, breast cancer, bone marrow transplantation, testicular cancer, AIDS- related malignancies, myleodysplasitc disorders, acute leukemia, congenital and cyclic neutropenias or aplastic anemia (see Mortsyn, et al.(1998) Filgrastim (r-metHuG-CSF). In Clinical Practice, 2 nd Ed., Marcel Dekker, Inc., New York, NY).
  • the formulation is administered to a patient at risk of infection.
  • the formulation is provided in a single dose during a course of chemotherapy. In some embodiments, the formulation is provided as multiple doses over the course of chemotherapy. In certain embodiments, the formulation is administered once daily, once weekly, once every two weeks or once a month. The formulation can be administered within twenty four hours of a dose of chemotherapy. In certain embodiments, the formulation is administered at least 14 days before a dose of chemotherapy. [0028] In certain embodiments, the formulation is administered as an injection. In some embodiments, the formulation is suitable for subcutaneous administration. In other embodiments, the formulation is suitable for intravenous administration. The formulation can also be provided as an orally available form, receives a dose at least about once a week. In other embodiments, the patient receives a dose at least about once every two weeks, at least about once every three weeks, or at least about once every month.
  • Another aspect of the invention relates to a process of making a protein conjugate and a conjugate made by the process comprising, reacting a protein with an activated polyethylene glycol-aldehyde in a reaction buffer comprising DMSO to covalently link the protein with the activated water-soluble polymer.
  • the process can also include removing substantially all unlinked water-soluble polymer to obtain said protein conjugate.
  • the polyethylene glycol-aldehyde is:
  • PEG is at least lOkD. In certain other embodiments, the PEG is at least 20kD. In specific embodiments, the PEG is 30kD or 40kD.
  • the PEG can be linked to the protein using any linker, including an alkyl linkage of from 1 to 30, 1 to 20, 1 to 15, 1 to 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 carbon atoms.
  • the process of the invention may allow the use of a reaction at a higher pH than other methods known in the art, such as substantially at neutral pH (about pH 7.0) (e.g., pegylation of a protein using aldehyde PEG (see, e.g., U.S. Patent No. 5,824,784).
  • substantially at neutral pH about pH 7.0
  • pegylation of a protein using aldehyde PEG see, e.g., U.S. Patent No. 5,824,784
  • the reaction is carried out at a pH of between 3 and 8.
  • the reaction is carried out at a pH of between about 4 and about 7, or about 4.5 and about 6 or about 5. In certain other embodiments, the reaction is carried out at a pH about neutral. In certain other embodiments, the reaction is carried out at a slightly acidic pH, such as, for example, about 5 or about 6.
  • the reaction buffer comprises a molar ratio of protein to activated water-soluble polymer of about 1 to about 3 to about 1 to about 60.
  • the reaction buffer comprises a molar ratio of protein to activated water- soluble polymer of about 1 to about 4, about 1 to about 5, about 1 to about 6, about 1 to about 7, about 1 to about 8, about 1 to about 9, about 1 to about 10, about 1 to about 15, about 1 to about 20, about 1 to about 25, about 1 to about 30, about 1 to about 35, about 1 to about 40, about 1 to about 45, about 1 to about 50, about 1 to about 55, about 1 to about 60.
  • the reaction buffer comprises a molar ratio of protein to activated water- soluble polymer of about 1 to about 7.
  • the removing of substantially all unreacted water-soluble polymer can be accomplished by methods known in the art such as, for example, dialysis or chromatography.
  • FIG. 1 Amino acid sequence of the predominant, fully processed human granulocyte colony stimulating factor (“G-CSF”) (SEQ ID NO:l). DNA sequence disclosed as SEQ ID NO: 2.
  • FIG. 2 Sequencing data for G-CSF protein used in Examples.
  • FIG. 2 discloses SEQ ID NOS 3 and 4, respectively, in order of appearance.
  • FIG. 3 Polyacrylamide Gel Electrophoresis of purified d-peg-GCSF produced according to the inventions.
  • Lane 1 Molecular weight size marker (in kD, 200, 116.3, 97.4, 66.3, 55.4, 36.5, 31 21.5, 14.4);
  • Lane 2 Purified d-peg-GCSF;
  • Lane 3 Unmodified GCSF
  • FIG. 4 Polyacrylamide Gel Electrophoresis of purified peg-GCSF produced by existing method without DMSO, but with the sample PEG and reaction conditions. Lane 1: Molecular weight size marker (in kD, 200, 116.3, 97.4, 66.3, 55.4, 36.5, 31 21.5, 14.4), Lane 2: Purified peg-GCSF
  • FIG. 5 Proliferative Effect of d-PEG-GCSF vs Reference (Neulasta) on
  • FIG. 6 Proliferative Effect of d-PEG-GCSF vs Reference (Neulasta) on
  • FIG. 7. Proliferative Effect of d-PEG-GCSF vs Neulasta on NFS60 cells
  • FIG. 8 In vivo assay of ANC over 5 day period after injection of the test compounds(d-PEG-GCSF vs Reference).
  • the present invention is based on the production of novel forms of mono- pegylated proteins, e.g., granulocyte colony stimulating factor ("G-CSF”) that are
  • DMSO dimethyl sulfoxide
  • the invention provides a G-CSF molecule that includes a PEG-molecule linked to Lysl6 (Lys 17 if a terminal methionine is included).
  • the invention also provides a method of linking an aldehyde-reactive PEG to a protein in the presence of DMSO.
  • the differentiated modification is such that the activity of the original molecule is preserved and the pharmacological profile of the molecule is improved.
  • N-terminus As used herein, the term "N-terminus,” “amino-terminus,” or analogous terms when used in the context of a covalent linkage of a protein to another molecule refer to a covalent linkage via the amino-terminal a-amino group of the protein.
  • wild type or “native” refers to a protein or polypeptide in its operative or functional form, typically as it is found naturally functioning in the body. These terms also refer to the protein in a form in which it has not been artificially modified or altered. The terms can thus relate to recombinant proteins. Accordingly, the terms can refer to a protein with an altered glycosylation pattern, including lack of glycosylation, relative to that as produced in the animal from which the nucleic acid and/or amino acid sequence of the protein was originally derived.
  • G-CSF granulocyte colony stimulating factor
  • granulocyte colony stimulating factor refers to a protein having the amino acid sequence set out in SEQ ID NO: 1 (FIG. 1) or an amino acid sequence substantially homologous thereto, whose biological properties relate to the stimulation of white blood cell production.
  • these terms include such proteins modified deliberately, as for example, by site directed mutagenesis or accidentally through mutations; such that they have additions, deletions, or substitutions of amino acid residues with respect to native G-CSF.
  • G-CSF refers to both the naturally occurring or recombinant protein, typically human, as obtained from any conventional source such as tissues, protein synthesis, cell culture with natural or recombinant cells.
  • Substantially homologous in reference to an amino acid sequence is defined herein as a sequence with at least 70%, typically at least about 80%, and more typically at least about 90% identity to another amino acid sequence, as determined by the FASTA search method in accordance with Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85, 2444-2448
  • conjugate in reference to a protein or polypeptide is a protein or polypeptide or population thereof, that functions in interaction with one or more other chemical groups attached by covalent bonds.
  • Proteins which can be conjugated with polymer units according to the present invention include non-mutated and mutated proteins such as but not limited to growth factors, antibodies, hormones, in particular therapeutically active proteins such as but not limited to erythropoietin, interferon alpha, interferon beta, interferon gamma, consensus interferon, G- CSF, GM-CSF, hemoglobin, interleukins such as interleukin-2 and interleukin-6, tumour necrosis factor, various cytokines, growth factors such as human growth factor and epidermal growth factor, immuno-globulins such as IgG, IgE, IgM, IgA, IgD and/or structural and/or functional variants and/or fragments thereof as well as their proteinoids or synthetic proteinlike forms.
  • non-mutated and mutated proteins such as but not limited to growth factors, antibodies, hormones, in particular therapeutically active proteins such as but not limited to erythropoietin, interferon alpha, inter
  • protein such as G-CSF useful in the practice of this invention may be of any form isolated from mammalian organisms, a product of prokaryotic or eukaryotic host expression of exogenous DNA sequences obtained by genomic or cDNA cloning or by DNA synthesis or alternatively a product of chemical synthetic procedures or by endogenous gene activation.
  • the protein can be of a natural or recombinant source obtained from tissue, mammalian- microbial cell cultures, plant cell cultures, transgenic animals, yeasts, fungi and/or transgenic plants.
  • Suitable prokaryotic hosts include various bacteria such as E. coli; suitable eukaryotic hosts include yeasts such as S. cerevisiae or Pichia pastoris, mammalian cells such as Chinese hamster ovary cells or monkey cells, transgenic animals such as mice, rabbit, goat, sheep, plant cell culture and transgenic plants such as
  • the protein expression product may be glycosylated with mammalian, plant or other eukaryotic carbohydrates, or it may be non-glycosylated.
  • the G-CSF expression product may also include an initial methionine amino acid residue at position 1.
  • the present invention contemplates the use of any and all such forms of G-CSF, although recombinant G-CSF, especially E.coli- derived, is typical. Certain G-CSF analogues have been reported to be biologically functional, and these may also be conjugated according to the present invention.
  • G-CSF analogues may include those having amino acid additions, deletions and/or substitutions as compared to the G-CSF amino acid sequence according to SEQ ID No. 1.
  • the sequence includes an insertion of amino acids as compared to SEQ ID No. 1, such as, for example, an insertion of VSE at positions 36, 37 and 38 of SEQ ID No. 1.
  • the sequence is as in SEQ ID No. 2 ( Figure 2).
  • the protein is one having the activity of G-CSF, including mutants of G-CSF, glycosylated G-CSF, non-glycosylated G-CSF and/or otherwise modified structural andlor functional variants of G-CSF.
  • the protein has the amino acid sequence of G-CSF identified in SEQ ID NO. 1 which corresponds to
  • G-CSF produced in bacteria, having 174 amino acids and an extra N-terminal methionyl residue.
  • Amino acid sequences of biological active G-CSF which differ from SEQ ID NO. 1 in that they do not contain a methionyl residue at position 1, are also included.
  • the invention relates to a composition
  • a composition comprising at least one population of G-CSF proteins wherein each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule and at least a 30% of the composition is not N- terminal pegylated.
  • each G-CSF molecule is covalently linked to a single polyethylene glycol molecule ("monopegylated G-CSF") and at least 30% of the composition is not N-terminally pegylated.
  • the composition comprises at least 80%> monopegylated G-CSF wherein at least 30%> of the composition is not N-terminally pegylated.
  • the composition comprises at least 85%, at least 90%> or at least 95% monopegylated G-CSF molecules wherein at least 30% of the composition is not N-terminally pegylated.
  • each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule through a particular lysine residue.
  • the invention comprises a composition having at least one G- CSF molecule covalently linked to at least one polyethylene glycol molecule via the amino terminus of the GCSF protein through an amine linkage.
  • the invention comprises a composition having at least one G-CSF molecule covalently linked to at least one polyethylene glycol molecule through Lysl6 (Lysl7 if an N-terminal methionine residue is counted).
  • the ratio of the N-terminally pegylated molecules to a second population, especially a second population at Lysl6 can range from less than about 1 to about 100, about 10 to about 90, about 20 to about 80, about 30 to about 70, about 40 to about 60, about 50 to about 50, about 60 to about 40, about 70 to about 30, wherein less than about 1 includes an amount undetectable using standard methods known in the art.
  • a substantially homogeneous composition comprising a monopegylated protein wherein at least 30% of the protein molecules are not pegylated at the N-terminal.
  • the composition comprises at least
  • the lysine is within 80, within 70, within 60, within 50, within 40, within 30, within 20, within 19, within 18, within 17, within 16, within 15, within 14, within 13, within 12, within 11, within 10, within 9, within 8, within 7, within 6, within 5, within 4, within 3 or within 2 amino acid residues from the N-terminal.
  • IPEG-protein conjugates have one PEG molecule linked to each protein molecule, that linkage may not necessarily be in the same location on each protein in the population.
  • dipegylated protein conjugates has two PEG molecules linked to each protein molecule, those linkages may not necessarily be in the same locations on each protein in the population.
  • the polymer-protein conjugates are typically prepared by reductive alkylation.
  • the present invention provides polymer-protein conjugates, wherein at least one nitrogen atoms of amino groups of the protein are each conjugated with a polymer unit via an amine linkage.
  • amino group includes primary and secondary amino groups and in particular NH- or NH 2 - groups in side-chains of amino acids such as NH 2 -groups in the side-chain of lysine, NH- or NH 2 -groups in the guanidino group of arginine or NH-groups in the imidazole side- chain of histidine.
  • the polymer unit generally comprises at least one polymer moiety and a linker moiety, which is between at least the one polymer moiety and the amine linkage.
  • the linker moiety may be linear or branched. If the linker moiety is branched, a polymer unit may comprise more than one polymer moiety.
  • the linker moiety is typically an aliphatic linker moiety. Suitable aliphatic linker moieties also include substituted alkyl diamines and triamines, lysine esters and malonic ester derivatives. The linker moieties are usually non- planar, so that the polymer chains are not rigidly fixed.
  • the linker moiety includes a multiple-functionalized alkyl group containing up to 18, and more typically from 1 to 10 carbon atoms.
  • a hetero-atom such as nitrogen, oxygen or sulfur may also be included within the alkyl chain.
  • the linker moiety may be branched, for example at a carbon or nitrogen atom. Examples for branched linker moieties and the resulting branched polymer units as well as methods for their preparation are described in WO 95/11 1924 and WO 03/1049699.
  • the linker moiety comprises at least one methylene group attached to the nitrogen atom of the amine linkage, e.g. from 1 to 12, from 1 to 10, from 1 to 8, from 1 to 7, from 1 to 6, from 1 to 5, or less, such as 4, 3, 2 or 1 and most typically two methylene groups which are directly attached to the nitrogen atom of the amine linkage.
  • polymers encompassed by instant invention include, but are not limited to, polyalkylene glycol and derivatives thereof, including PEG, methoxylated PEG
  • mPEG PEG homopolymers
  • polypropylene glycol homopolymers polypropylene glycol homopolymers
  • copolymers of ethylene glycol with propylene glycol wherein said homopolymers and copolymers are unsubstituted or substituted at one end with an alkyl group.
  • the polymer is mPEG and most often mono-methoxylated PEG.
  • the water soluble polymers can be linear, branched, or star- shaped with a wide range of molecular weights.
  • the size of the PEG can range from 10 to about 100 kD. In specific embodiments, the size of the PEG is about 10 to about 50 kD.
  • the molecular weight of a polyethylene glycol moiety attached to a amino group is from 2 to 100 kDa, more typically from 5 to 60 kDa and most typically from 10 to 30 kDa.
  • the number n of ethylene oxide residues in a polyethylene glycol moiety is from about 40 to about 2270, more typically from about 110 to about 1370 and most typically from about 225 to about 680.
  • the polymer moiety is usually a substantially non-antigenic or non- immunogenic polymer chain.
  • the polymer moieties used are typically selected from among water-soluble polymer moieties. This has the advantage that the protein to which the water-soluble polymer moieties are attached or conjugated does not precipitate in an aqueous environment such as a physiological environment.
  • the polymer selected should further have a single reactive aldehyde, so that the degree of polymerization may be controlled as provided for in the present processes.
  • the polymer unit as well as the polymer moiety may be branched or unbranched. Typically, for therapeutic use of the end- product preparation, the polymer will be pharmaceutically acceptable.
  • One skilled in the art will be able to select the desired polymer moiety based on considerations such as whether the polymer-protein conjugate will be used therapeutically, and if so, the desired dosage, circulation time, resistance to proteolysis and other considerations.
  • the polymer moiety may be selected from the group consisting of polyalkylene glycol moieties, polysaccharide moieties such as dextran and its derivatives, polysaccharide and its derivatives, pyrrolidone moieties such as polyvinyl pyrolidone, cellulose moieties such as carboxymethyl cellulose, polyvinyl alcohol, poly- 1,3-dioxolan, poly- 1,3,6- trioxane, ethylene-maleic anhydride copolymer, polyaminoacid moieties and/or polyacrylamide moieties and/or other similar non-immunogenic polymer moieties (either homopolymers or random copolymers) and/or derivatives thereof.
  • Such polymers are also capable of being functionalized or activated for inclusion in the present invention.
  • the polymer moiety is a polyalkylene glycol moiety.
  • polyalkylene glycol designates polyalkylene glycol radicals or polyalkylene glycol moieties, where the alkylene radical is a straight or branched chain radical.
  • polyalkylene glycol also comprises polyalkylene glycols formed from mixed alkylene glycols such as polymers containing a mixture of polyethylene and polypropylene radicals and polymers containing a mixture of polyisopropylene, polyethylene and polyisobutylene radicals.
  • a polyalkylene glycol moiety in the polymer protein conjugates according to the present invention is usually a polyethylene glycol moiety or polyethylene glycol residue formed by removal of the two terminal hydroxyl groups.
  • a-substituted polyalkylene oxide derivatives such as methoxy polyethylene glycols (mPEG) or other suitable alkyl substituted polyalkylene oxide derivatives such as those containing mono- or bis-terminal C 1 -C4 groups.
  • mPEG methoxy polyethylene glycols
  • suitable alkyl substituted polyalkylene oxide derivatives such as those containing mono- or bis-terminal C 1 -C4 groups.
  • Straight-chained non-antigenic polymers such as monomethyl polyethylene glycol homopolymers are typical.
  • Alternative polyalkylene oxides such as other polyethylene glycol homopolymers,
  • polyethylene glycol heteropolyrners other alkyl polyalkylene oxide block copolymers and copolymers of block copolymers of polyalkylene oxides are also useful.
  • activation methoxylated PEG
  • mPEG methoxylated PEG
  • mPEG can be activated for subsequent covalent attachment to amino groups by methods well known in the art, i.e., mPEG can be modified to contain varying reactive moieties suitable for subsequent attachment to proteins via amino acid residues containing available amino residues, e.g., lysinyl residues.
  • the PEG reagent used in the process according to the present invention is usually a reagent having the formula: [R-L 1 -(CH 2 -CH 2 -0), n ]y-L 2 -(CH 2 ) m -i-CFiO, wherein R is H, a lower alkyl, aryl or any suitable protecting group; n is an integer representing the number of ethylene oxide residues in a polyethylene glycol moiety; m is an integer representing the number of methylene groups; L 1 is 0 , N, S andor a branched or non-branched linker moiety which can be absent or present; L 2 is a branched or non-branched linker moiety which can be absent or present; and y is an integer with the proviso that y is 1 in the absence of L 2 and y is at least 1 in the presence of L 2 .
  • the PEG is PEG acetaldehyde, most typically a methox
  • a process of making a protein conjugate and a conjugate made by the process comprising, reacting a protein with an activated polyethylene glycol-aldehyde in a reaction buffer comprising DMSO to covalently link the protein with the activated water- soluble polymer.
  • the process can also include removing substantially all unlinked water- soluble polymer to obtain said protein conjugate.
  • the polyethylene glycol-aldehyde is
  • the PEG is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • the PEG is at least 20kD.
  • the PEG is 30kD or 40kD.
  • the reducing agent used in the reactive alkylation is usually selected from, but not limited to, NaCNBH 4 or NaBH 4 .
  • the reaction is performed at a protein concentration from 0.5 to 100 mg/ml, more typically from 1 to 10 mg/ml and most typically from 3 to 7 mg/ml.
  • the reaction can also be performed at a protein -to-polymer molar ratio of from 1 : 1 to 1 :400, and typically from 1 :5 to 1 :30 and most typically from 1 : 15 to 1 :30.
  • the reaction buffer comprises a molar ratio of protein to activated water-soluble polymer of about 1 to about 3 to about 1 to about 60.
  • the reaction buffer comprises a molar ratio of protein to activated water-soluble polymer of about 1 to about 4, about 1 to about 5, about 1 to about 6, about 1 to about 7, about 1 to about 8, about 1 to about 9, about 1 to about 10, about 1 to about 15, about 1 to about 20, about 1 to about 25, about 1 to about 30, about 1 to about 35, about 1 to about 40, about 1 to about 45, about 1 to about 50, about 1 to about 55, about 1 to about 60.
  • the reaction buffer comprises a molar ratio of protein to activated water-soluble polymer of about 1 to about 7.
  • the removing of substantially all unreacted water-soluble polymer can be accomplished by methods known in the art such as, for example, dialysis or chromatography.
  • the invention in particular, encompasses the pegylation of therapeutic polypeptides.
  • the therapeutic protein for use in accordance with the methods of the invention may be, e.g., a protease, pituitary hormone protease inhibitor, poietin, colony stimulating factor, hormone, clotting factor, anti-clotting factor, neurotropic factor, rheumatoid factor, CD protein, osteoinductive factor, interleukin, growth factor, interferon, cytokine, somatomedian, chemokine, immunoglobulin, gonadotrophin, interleukin, chemotactin, interferon, lipid-binding protein allergen, or a combination of the foregoing.
  • Such therapeutic proteins include, interferon-a2A, interferon-a2B, interferon ⁇ , interferon- ⁇ , insulin- like growth factor- 1 (IGF-1), insulin- like growth factor-2 (IGF2), insulin, human growth hormone (hGH), transforming growth factor (TGF), erythropoietin (EPO), ciliary neurite transforming factor (CNTF), thrombopoietin (TPO), brain-derived neurite factor (BDNF), IL-1, insulintropin, IL-2, glial-derived neurite factor (GDNF), IL-1 RA, tissue plasminogen activator (tPA), superoxide dismutase (SOD), urokinase, catalase, streptokinase, fibroblast growth factor (FGF), hemoglobin, neurite growth factor, adenosine deamidase (NGF), granulocyte macrophage colony stimulating factor (GM-CSF), bovine growth hormone (BGH
  • the reaction may be performed in the presence of a buffer.
  • the buffer may be selected from a phosphate, acetate, HEPES, MES, or other similar buffers.
  • the reaction buffer can generally be a standard buffer free of amine components, e.g., phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • the reaction buffer usually includes a salt, e.g., Na, concentration of about 0.1 mM to about lOOmM, most often about lmM to about 50mM, and even more often about lOmM to about 20mM.
  • the polypeptide is mixed with the dry activated water-soluble polymer under stirring.
  • the reaction buffer usually has a pH of about 6.5 to about 8.5 or about 6.6 to about 7.5. In certain embodiments, the reaction buffer has a neutral pH of about 7.0.
  • the reaction buffer further comprises an organic solvent, and in particular, dimethyl sulfoxide ("DMSO").
  • DMSO dimethyl sulfoxide
  • the DMSO may be present in the reaction mixture in concentration of 5-80% and, typically 10-40% (v/v).
  • DMSO is widely used as a general solvent, but not typically for affecting pegylation reactions, in particular, for preferentially affecting the resulting sites of pegylation of said reaction away from a protein N-terminal.
  • PCT Publication WO 08/019214 describes a process of selective preparation of N-terminal modified erythropoietin in a DMSO-containing buffer.
  • the PEG linkage provided a carbamate linked PEG-EPO selectively at the N-terminal of the protein.
  • reaction conditions described herein including use with an aldehyde-conjugated PEG, appear to specifically drive the covalent conjugation of the activated PEG toward particular lysine sites.
  • addition of DMSO to the reaction buffer alters the sites of pegylation.
  • the addition of DMSO to the reaction buffer as described herein drives the reaction toward the preferential pegylation of the protein at Lysl7. Accordingly, the methods of the invention allow for selective modification of specific amino groups of the protein of interest, in particular, modification of lysine residues near the amino terminus of the protein.
  • the reaction is typically performed at a temperature from 2°C to 50°C, more usually at a temperature from 2°C to 8°C and most typically about 4°C.
  • the selection of a specific temperature may affect the reaction time, which is to be chosen such that polymer- protein conjugates with two nitrogen atoms of amino groups of the protein being conjugated with a polymer unit via an amine linkage are generally prepared.
  • the activated water-soluble polymer will be present in molar excess and as such, the unreacted excess activated water-soluble polymer will need to be removed from newly formed protein conjugates.
  • "removing substantially all unlinked water-soluble polymer” refers to generally known methods for carrying out such a separation, e.g., through dialysis. Generally, about 80% of unlinked water-soluble polymer is removed, typically about 90%> is removed, more typically about 95%) is removed and most typically about 99% is removed.
  • the invention relates to a pharmaceutical formulation comprising at least one population of G-CSF proteins wherein each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule, optionally in a pharmaceutically acceptable carrier.
  • the carrier is substantially protein free.
  • the pharmaceutical formulation comprises at least one population of G-CSF proteins wherein each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule and at least a 30% of the composition is not N-terminal pegylated.
  • each G-CSF molecule is covalently linked to a single polyethylene glycol molecule ("monopegylated G-CSF") and at least 30%> of the composition is not N-terminally pegylated.
  • the formulation comprises at least 80% monopegylated G-CSF wherein at least 30% of the composition is not N-terminally pegylated.
  • the formulation comprises at least 85%, at least 90% or at least 95%) monopegylated G-CSF molecules wherein at least 30%> of the composition is not N-terminally pegylated.
  • each G-CSF molecule is covalently linked to at least one polyethylene glycol molecule through a particular lysine residue.
  • the formulation includes at least one G-CSF molecule covalently linked to at least one polyethylene glycol molecule via the amino terminus of the G-CSF protein through an amine linkage.
  • the formulation comprises at least one G-CSF molecule covalently linked to at least one polyethylene glycol molecule through Lysl6 (Lysl7 if an N-terminal methionine residue is counted).
  • the ratio of the N-terminally pegylated molecules to a second population, especially a second population at Lysl6 can range from less than about 1 to about 100, about 10 to about 90, about 20 to about 80, about 30 to about 70, about 40 to about 60, about 50 to about 50, about 60 to about 40, about 70 to about 30, wherein less than about 1 includes an amount undetectable using standard methods known in the art.
  • the G-CSF molecules and compositions of the invention are expected to exhibit prolonged stability under standard storage conditions, i.e., storage at standard temperature, e.g., about 25 °C for example for at least three months.
  • the protein-free carrier is serum-free, albumin-free or human serum albumin-free ("hsa- free")).
  • the pharmaceutical formulations may be stored for extended period of time without substantial and/or detectable degradation of G-CSF as determined by methods described herein and/or known in the art.
  • the pharmaceutical formulations of the invention are stable (i.e., do not exhibit detectable and/or do not exhibit substantial degradation) as determined at least 15 months after storage at about - 20°C or 4°C.
  • the pharmaceutical formulations of the invention are stable (i.e., do not exhibit detectable and/or do not exhibit substantial degradation) as determined at least 10 months after storage at about 25°C or about 37°C.
  • the stability of pharmaceutical formulations of the invention may be assessed by any method known in the art.
  • the stability of the pharmaceutical formulations of the invention is assessed by monitoring alteration in the protein concentration over time as determined by a bicinchoninic acid ("BCA") protein assay.
  • BCA bicinchoninic acid
  • the stability of the pharmaceutical formulations of the invention is assessed by indication of protein degradation (i.e., G-CSF conjugate degradation) over time as determined by SDS PAGE analysis.
  • the stability can be measured by analyzing breakdown of the product by an HPLC.
  • the stability of the pharmaceutical formulations of the invention is assessed by monitoring the activity of said formulation over time, wherein said activity is determined by any in vitro or in vivo method known in the art for determination of activity of said formulation (e.g., G-CSF activity).
  • the activity of a pharmaceutical formulation of the invention comprising a plurality of G-CSF-conjugates is evaluated by the ability of said pharmaceutical formulation in an invitro bioassay utilizing a G-CSF dependent clone of murine 32D cells.
  • the acitivyt of the formulation is measured in vivo in its capacity to alter white blood cell count in experimental animals, such as hamsters.
  • a pharmaceutical formulation comprising a monopegylated protein wherein at least 30% of the protein molecules are not pegylated at the N-terminal.
  • the formulation comprises at least 30% monopegylated proteins which are pegylated at a lysine residue within 100 amino acids of the N-terminal.
  • the lysine is within 80, within 70, within 60, within 50, within 40, within 30, within 20, within 19, within 18, within 17, within 16, within 15, within 14, within 13, within 12, within 11, within 10, within 9, within 8, within 7, within 6, within 5, within 4, within 3 or within 2 amino acid residues from the N-terminal.
  • the formulations of the invention may be further rendered suitable for injection by mixture or combination with an additional pharmaceutically acceptable carrier or vehicle by methods known in the art.
  • pharmaceutically acceptable carriers for formulating the products of the invention are saline, human serum album, human plasma proteins, etc.
  • the invention also relates to pharmaceutical compositions comprising a conjugate as described above and a pharmaceutically acceptable excipient and/or carrier.
  • Such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.
  • compositions comprising effective amounts of polymer- protein conjugates of the present invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.
  • Such compositions includes diluents of various buffer content, such as Tris-HC 1 , acetate, phosphate, pH and ionic strength; additives such as detergents and solubilizing agents such as Tween 80, Polysorbate 80, antioxidants such as ascorbic acid and sodium metabisulfite, preservatives such as benzyl alcohol and bulking substances such as lactose or mannitol; incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc.
  • the protein conjugates prepared in accordance with this invention may be formulated in pharmaceutical compositions suitable for injection with a pharmaceutically acceptable carrier or vehicle by methods known in the art. See, e.g., W097/09996,
  • the compounds of the present invention may be formulated, for example, in 10 mM sodium/potassium phosphate buffer at pH 7 containing a tonicity agent, e.g. 132 mM sodium chloride.
  • a tonicity agent e.g. 132 mM sodium chloride.
  • the pharmaceutical composition may contain a preservative.
  • the pharmaceutical compositions generally comprise a conjugate, a multiply charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range of from about 5.5 to about 7.0, and optionally one or more pharmaceutically acceptable carriers and/or excipients.
  • a method of increasing white cell count in a host comprising administering a pharmaceutical formulation of the invention to a host in need thereof.
  • the host is human.
  • the hosts are at risk of or suffering from neutropenia.
  • the hosts are being treated with an agent that decreases their white blood cell count.
  • the hosts have decreased endogenous levels of G-CSF.
  • the hosts are undergoing radiation treatment.
  • the hosts can be suffering from lung cancer, lymphoma, breast cancer, bone marrow transplantation, testicular cancer, AIDS- related malignancies, myleodysplasitc disorders, acute leukemia, congenital and cyclic neutropenias or aplastic anemia (see Mortsyn, et al.(1998) Filgrastim (r-metHuG-CSF). In Clinical Practice, 2 nd Ed., Marcel Dekker, Inc., New York, NY).
  • the formulation is administered to a patient at risk of infection.
  • the formulation is provided in a single dose during a course of chemotherapy. In some embodiments, the formulation is provided as multiple doses over the course of chemotherapy. In certain embodiments, the formulation is administered once daily, once weekly, once every two weeks or once a month. The formulation can be administered within twenty four hours of a dose of chemotherapy. In certain embodiments, the formulation is administered at least 14 days before a dose of chemotherapy.
  • the formulation is administered as an injection.
  • the formulation is suitable for subcutaneous administration.
  • the formulation is suitable for intravenous administration.
  • the formulation can also be provided as an orally available form, receives a dose at least about once a week.
  • the patient receives a dose at least about once every two weeks, at least about once every three weeks, or at least about once every month.
  • the therapeutically effective amount is that amount of conjugate necessary for the in vivo biological activity of causing bone marrow cells to increase production of white blood cells.
  • the exact amount of conjugate is a matter of preference subject to such factors as the exact type of condition being treated, the condition of the patient being treated, as well as other ingredients in the composition.
  • the pharmaceutical formulations containing the conjugate may be formulated at a strength effective for administration by various means to a human patient experiencing disorders characterized by low or defective white blood cell production.
  • Average therapeutically effective amounts of the conjugate may vary and in particular should be based upon the recommendations and prescription of a qualified physician. For example, 0.01 to 10 ⁇ g per kg body weight, typically 0.1 to 3 ⁇ g per kg body weight, may be administered e.g. once a chemotherapy cycle. Alternatively, the
  • compositions of the invention may contain a fixed dose of the conjugate, e.g. from 1 to 10 mg, or from 2-9 or about 6mg in a fixed dose formulation useful for a host over 45kg.
  • a fixed dose of the conjugate e.g. from 1 to 10 mg, or from 2-9 or about 6mg in a fixed dose formulation useful for a host over 45kg.
  • the pharmaceutical compositions containing the conjugates of the invention may be formulated at a strength effective for administration by various means to a human patient experiencing disorders characterized by low or defective white blood cell production. Average therapeutically effective amounts of the conjugate may vary and should be based upon the recommendations and prescription of a qualified physician.
  • Example 1 Procedure for the generation of differentiated PEG-GCSF (d-PEG-GCSF) using aldehvde-PEGPOK) in the presence of DMSO.
  • the products of the reaction were purified, and un-reacted PEG molecule removed by SP-column chromatography at pH4, in 10 mM sodium acetate buffer.
  • the bound pegylated molecules was eluted by step gradient of: (1) 50 mM NaCl, pH4, (2) 25 mM NaCl, pH5, (3) 40 mM NaCl, pH5.5, (4) 70 mM NaCl, pH5.5 and (5) 50 mM NaCl, pH6.5.
  • the pegylated GCSF product was eluted between first and second step.
  • Figure 3 shows the PAGE (polyacrylamide gel electrophoresis) image of purified sample, as a single band species.
  • d-PEG-GCSF refers to the product made with aldehyde-PEG(30K) produced with the DMSO included in the process
  • NeulastaTM refers to the product made with aldehyde-PEG (20K) produced without DMSO in the process.
  • Neulasta is a Trade Mark of Amgen.
  • Example 2 In vitro study to show d-PEG-GCSF is equivalent to Neulasta with two samples, (lot DM-8205 and 8201K16)
  • concentrations of test compounds and the growth of drug-exposed cells was compared to the growth in wells with medium only. After 72 hours of incubation at 37°C in a 5% C0 2 humidified incubator, the cells were exposed to medium containing 5 mg/ml of MTT(*) and further incubated for 4.5 hours in the same incubator. The metabolism of MTT by the cells were quenched by addition of acidified 25% SDS in water. The plates were left at room temperature to dissolve the cells. The dissolve materials were gently shaken to homogeneity for 5 minutes, and the absorbance of the content in each well were read on a
  • MTT is abbreviation for 3-(4,5-Dimethyl-2-thiazolyl)-2,5- diphenyl-2HterazoliumBromide); obtained from Sigma (MO, catalog M2128).
  • Example 4 In vitro and in vivo comparison d-PEG-GCSF and Neulasta (lot 1PN7606).
  • d-PEG-GCSF (lot 1PN7606) had slightly better in vitro activity than Neulasta. These samples were prepared more than 3 months before the testing.
  • the blood samples were analyzed for estimation of total WBC (white blood cells) using a veterinary cell counter.
  • Peripheral blood smears were examined for estimation of the differential cell counts.
  • Absolute neutrophil counts (ANC) were calculated using the percentage of neutrophils in the blood.
  • the area under the curve (AUC) of ANC vs. time was calculated using trapezoidal rule for each animal. The AUC data is plotted against the dosage as shown in Figure 8.
  • pegylation site was assigned to N terminus. If a sequence of XXLE or LXXLE were detected then pegylation site was assigned to N terminus. If lysine was not detected or detected at much lower levels than leucine , then pegylation site of Lys- 16 was assigned. Note that we count our sequence site as 1 at Thr. If we were to count met at site 1 than lysine 16 would be assigned as lysine 17. The result is summarized Table 2 below.
  • Example 6 Measurements of In vitro activity.
  • the G-CSF in vitro bioassay is a mitogenic assay utilizing a G-CSF dependent clone of murine 32D cells.
  • Cells are maintained in Iscoves medium containing 5% FBS and 20 ng/ml G-CSF.
  • Prior to sample addition cells are prepared by rinsing twice with growth medium lacking G-CSF.
  • An extended twelve point G-CSF standard curve is prepared, ranging from 48 to 0.5ng/ml (equivalent to 4800 to 50 IU/ml).
  • Four dilutions, estimated to fall within the linear portion of the standard curve, (1000 to 3000 IU/ml) are prepared for each sample and run in triplicate.
  • the pegylated G-CSF samples can be diluted
  • a volume of 40 ul of each dilution of sample or standard is added to appropriate wells of a 96 well microtiter plate containing 10,000 cells/well. After forty-eight hours at 37°C and 5.5% C0 2 0.5umCi of methyl- 3 H- thymidine is added to each well. Eighteen hours later, the plates are harvested and counted. A dose response curve (log G-CSF concentration vs. CPM-background) is generated and linear regression analysis of points which fall in the linear portion of the standard curve performed. Concentrations of unknown test samples can be determined using the resulting linear equation and correction for the dilution factor.
  • Example 7 Measurements of In vivo activity.
  • the in vivo testing can be carried out by dosing male golden hamsters with a
  • Stability can be assessed in terms of breakdown of product, as visualized using
  • Pegylated G-CSF are studied in two pH levels, pH 4.0 and pH 6.0 at 4°C, each for up to 16 days. Elevating the pH to 6.0 provides an environment for accelerated stability assays.
  • monopegylated G-CSF as prepared above are placed in a buffer containing 20 mM sodium phosphate, 5 mM sodium acetate, 2.5 % mannitol, 0.005 % TWEEN80, pH 6.0 at a final protein concentration of 0.25 mg/ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne de nouveaux conjugués de protéines, en particulier de nouvelles protéines pégylées, et sur leurs procédés de fabrication et d'utilisation. Un aspect de la présente invention concerne un G-CSF pégylé dont l'efficacité et la stabilité sont inattendues par rapport à des formulations courantes de G-CSF.
PCT/US2010/050671 2009-09-30 2010-09-29 Facteur modifié de stimulation des colonies de granulocytes (g-csf) WO2011041376A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24738909P 2009-09-30 2009-09-30
US61/247,389 2009-09-30

Publications (1)

Publication Number Publication Date
WO2011041376A1 true WO2011041376A1 (fr) 2011-04-07

Family

ID=43826620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/050671 WO2011041376A1 (fr) 2009-09-30 2010-09-29 Facteur modifié de stimulation des colonies de granulocytes (g-csf)

Country Status (4)

Country Link
AR (1) AR078205A1 (fr)
CL (1) CL2010001049A1 (fr)
TW (1) TW201138831A (fr)
WO (1) WO2011041376A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120042613A1 (en) * 2010-06-22 2012-02-23 Sandoz Ag Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF
US8765924B2 (en) 2006-08-04 2014-07-01 Prolong Pharmaceuticals, Inc. Modified erythropoietin
WO2016201448A3 (fr) * 2015-06-11 2017-02-09 Prolong Pharmaceuticals, LLC Facteur de stimulation des colonies de granulocytes pégylés (gcsf)
WO2021188869A3 (fr) * 2020-03-20 2021-12-02 Amgen Inc. Détermination de l'extrémité n-terminale libre de pegfilgrastim à l'aide d'une protéase acide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060154865A1 (en) * 2004-12-22 2006-07-13 Beat Amrein Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
US20070014763A1 (en) * 2005-06-01 2007-01-18 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
US20070083006A1 (en) * 2003-04-11 2007-04-12 Pr Pharmaceuticals, Inc. Method for preparation of site-specific protein conjugates
US20070092482A1 (en) * 2005-08-04 2007-04-26 Bossard Mary J Conjugates of a G-CSF moiety and a polymer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083006A1 (en) * 2003-04-11 2007-04-12 Pr Pharmaceuticals, Inc. Method for preparation of site-specific protein conjugates
US20060154865A1 (en) * 2004-12-22 2006-07-13 Beat Amrein Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
US20070014763A1 (en) * 2005-06-01 2007-01-18 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
US20070092482A1 (en) * 2005-08-04 2007-04-26 Bossard Mary J Conjugates of a G-CSF moiety and a polymer

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765924B2 (en) 2006-08-04 2014-07-01 Prolong Pharmaceuticals, Inc. Modified erythropoietin
US20120042613A1 (en) * 2010-06-22 2012-02-23 Sandoz Ag Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF
US8449873B2 (en) * 2010-06-22 2013-05-28 Sandoz Ag Long-term storage of non-glycosylated recombinant Human G-CSF
WO2016201448A3 (fr) * 2015-06-11 2017-02-09 Prolong Pharmaceuticals, LLC Facteur de stimulation des colonies de granulocytes pégylés (gcsf)
JP2018519359A (ja) * 2015-06-11 2018-07-19 アンビオ ファーマシューティカルズ，エルエルシー Ｐｅｇ化顆粒球コロニー刺激因子（ｇｃｓｆ）
WO2021188869A3 (fr) * 2020-03-20 2021-12-02 Amgen Inc. Détermination de l'extrémité n-terminale libre de pegfilgrastim à l'aide d'une protéase acide

Also Published As

Publication number Publication date
CL2010001049A1 (es) 2011-04-15
TW201138831A (en) 2011-11-16
AR078205A1 (es) 2011-10-19

Similar Documents

Publication Publication Date Title
TWI364295B (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US7893019B2 (en) G-CSF site-specific mono-conjugates
AU736067B2 (en) Erythropoietin derivatives
CN1729018B (zh) G-csf偶联物
AU739359B2 (en) Improved interferon polymer conjugates
JP4190184B2 (ja) ポリエチレングリコールを有するエリスロポエチン接合体
US20070166278A1 (en) Novel g-csf conjugates
WO2006094530A1 (fr) Conjugues de proteines et de dipolymeres et leurs procedes de preparation
JP5961730B2 (ja) 修飾されたエリスロポエチン
KR101549457B1 (ko) 폴리에틸렌글리콜과 과립구 콜로니 자극인자(g-csf)의 신규 접합체
EP2236521A1 (fr) G-csf modifié par du polyéthylène glycol de type y, méthode de préparation et son utilisation
WO2011041376A1 (fr) Facteur modifié de stimulation des colonies de granulocytes (g-csf)
US20050281778A1 (en) Human growth hormone conjugated with biocompatible polymer
US20040204566A1 (en) Chemically-modified G-CSF
EP1869079A2 (fr) Conjugues di-polymere-proteine et procedes de preparation de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10821151

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10821151

Country of ref document: EP

Kind code of ref document: A1